China SXT Pharmaceuticals (SXTC) Invested Capital: 2018-2025
- China SXT Pharmaceuticals' Invested Capital rose 34.03% to $20.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.3 million, marking a year-over-year increase of 34.03%. This contributed to the annual value of $15.5 million for FY2025, which is 10.60% up from last year.
- China SXT Pharmaceuticals' Invested Capital amounted to $20.3 million in Q3 2025, which was up 30.71% from $15.5 million recorded in Q1 2025.
- China SXT Pharmaceuticals' Invested Capital's 5-year high stood at $28.1 million during Q1 2021, with a 5-year trough of $5.2 million in Q3 2023.
- Its 3-year average for Invested Capital is $14.2 million, with a median of $15.0 million in 2023.
- In the last 5 years, China SXT Pharmaceuticals' Invested Capital skyrocketed by 197.84% in 2021 and then crashed by 67.80% in 2023.
- Over the past 5 years, China SXT Pharmaceuticals' Invested Capital (Quarterly) stood at $15.9 million in 2021, then climbed by 1.17% to $16.1 million in 2022, then plummeted by 67.80% to $5.2 million in 2023, then soared by 192.31% to $15.2 million in 2024, then surged by 34.03% to $20.3 million in 2025.
- Its Invested Capital stands at $20.3 million for Q3 2025, versus $15.5 million for Q1 2025 and $15.2 million for Q3 2024.
